|
Erythema Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The previously reported primary endpoint of this study was freedom from target lesion failure (TLF: a composite of cardiac death, target vessel-related myocardial infarction [MI] and clinically-indicated target lesion revascularization) at 9 months.
|
31033154 |
2020 |
|
Erythema Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patient-oriented composite endpoint (POCE; all-cause death, any myocardial infarction (MI), any revascularization) and target lesion failure (TLF: cardiac death, target-vessel MI, target lesion revascularization) were analyzed.
|
31642213 |
2020 |
|
Erythema Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CKD chronic kidney disease, POCE patient oriented composite endpoint, MACE major adverse cardiovascular events, TLF target lesion failure, TLR target lesion revascularization, ST stent thrombosis.
|
31792571 |
2019 |
|
Erythema Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The primary ischemic-safety and bleeding-safety endpoints were TLF (composite of cardiac-death, target vessel MI, and clinically driven target lesion revascularization), and BARC major bleedings (≥type-3a) at 1-year follow-up.
|
30917900 |
2019 |
|
Erythema Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The primary device-oriented endpoint (Target Lesion Failure, TLF) was defined as a combination of cardiovascular death, target vessel myocardial infarction or clinically driven target lesion revascularization.Among the cardiac risk factors, NSTE-ACS patients were more frequently smokers (P = 0.028), had less frequently dyslipidemia (P = 0.003) and a history of prior PCI (P < 0.01).The median follow-up was 1070[763-1197] days.
|
29630530 |
2018 |
|
Erythema Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Study endpoints were CI-AKI, and all-cause death and target-lesion failure (TLF: cardiac death, target-vessel myocardial infarction, or target-lesion revascularization) on follow-up.
|
30269828 |
2018 |
|
Erythema Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) is a large-scale, prospective, multicentre, randomised single-blind, controlled, non-inferiority trial conducted at 58 study sites globally, including Europe, Japan and Korea, powered to prove non-inferiority for freedom from target lesion failure (TLF: cardiac death, target vessel-related myocardial infarction [MI] and target lesion revascularisation) at nine months.
|
29790479 |
2018 |
|
Erythema Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EVOLVE II randomised, controlled trial proved the non-inferiority of the SYNERGY versus the PROMUS Element Plus stent for one-year target lesion failure (TLF: ischaemia-driven target lesion revascularisation [ID-TLR], target vessel myocardial infarction [TVMI], or cardiac death).
|
27840326 |
2017 |
|
Erythema Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The primary endpoints included the incidence of SF and a composite major adverse cardiac event [MACE, including myocardial infarction (MI), cardiac death, and target-vessel revascularization (TVR)] at 1-year follow-up and at the end of follow-up for overall patients, and target lesion failure [TLF, including cardiac death, target vessel myocardial infarction (TVMI) and target lesion revascularization (TLR)] at the end of study for SF patients.
|
28631105 |
2017 |
|
Erythema Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary device-oriented endpoint (target lesion failure [TLF]) was defined as a combination of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization.
|
28259663 |
2017 |